Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amoxicillin-clavulanate + doxycycline is an antibiotic combination therapy consisting of two different classes of antibiotics. Amoxicillin-clavulanate combines amoxicillin (a penicillin-type antibiotic effective against gram-positive and gram-negative bacteria) with clavulanate (a beta-lactamase inhibitor that prevents bacterial enzymes from inactivating amoxicillin). Doxycycline is a tetracycline-class antibiotic that works by inhibiting bacterial protein synthesis. This combination is generally not recommended as a first-line treatment option because tetracycline antibiotics (like doxycycline) can reduce the effectiveness of penicillin-type antibiotics (like amoxicillin)[1][2]. Laboratory studies have shown that when used together, doxycycline may interfere with amoxicillin's bactericidal activity, potentially making amoxicillin less effective[1]. However, in specific clinical scenarios such as recurrent/progressive periodontitis, sequential administration (using one antibiotic followed by the other) has shown some benefit compared to single antibiotic regimens[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin-clavulanate + doxycycline.